Clinical Trial Update: A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating subcutaneous C1-esterase inhibitor for prevention of hereditary angioedema completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• C1-esterase inhibitor

Snippet

Sponsor: CSL Behring | Conditions: Hereditary Angioedema Types I and II | Phase 3 | Status: COMPLETED | Results posted: 2021-01-29